USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Strategic Analysis of Opportunities in the CRO Market - Phase 0
Strategic Analysis of Opportunities in the CRO Market - Phase 0
RELEASE DATE
29-Sep-2008
29-Sep-2008
REGION
North America
North America
Research Code: M217-01-00-00-00
SKU: HC01703-NA-MR_06410
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
HC01703-NA-MR_06410
Description
This strategic analysis study attempts to understand the opportunities for contract research organisations and pharmaceutical companies to take advantage of the inevitable choice of Phase zero or Microdosing studies in the drug development process. The background of microdosing, industry challenges, regulatory guidelines and competitive analysis are discussed in detail.
Table of Contents
Research Process
- Scope and Objective
Challenges Faced by the CROs
- Consolidation within the CRO Industry to Threaten Customer Relationship
- Electronic Data Capture Threatens Revenues
- Risk Sharing Model Necessitates Proper Positioning of Services
- Regional Disparities Affect Competitive Pricing of Services
Phase Zero
- CRO Contribution to Drug Development
- Human Microdosing
- Technologies Used in Microdosing
- Advantages of Microdosing
- FDA and EMEA Regulations
- The EUMAPP Program
- Concerns about Microdosing
- Revenue Forecasts
- Future Outlook
Profiles of Key Industry Participants
- Accium Biosciences
- Radiant Research
- Vitalea Science
- Xceleron
Approaches to Microdosing
Popular Topics
This strategic analysis study attempts to understand the opportunities for contract research organisations and pharmaceutical companies to take advantage of the inevitable choice of Phase zero or Microdosing studies in the drug development process. The background of microdosing, industry challenges, regulatory guidelines and competitive analysis are discussed in detail.
| No Index | Yes |
|---|---|
| Podcast | No |
| Industries | Healthcare |
| WIP Number | M217-01-00-00-00 |
| Is Prebook | No |